The Good, The Bad, And The Uncertain: Trump’s Second Administration And The Rx Industry
The pharma industry arguably suffered none of the downside risks that were possible during the first Trump administration, and their relationship with Biden could not have gone much worse. And while they may hope a Trump return could help their fortunes, having RFK Jr. supervising the FDA is likely not the prescription they want.
More from Outlook
The financial macroenvironment may be looking more favorable for 2025 but will pharma growth be muted by elements beyond its control? In Vivo discusses the headwinds and drivers for pharma in the coming 12 months.
Despite the stellar success of the class so far, biotech is now looking past GLP-1s to more tolerable, sustainable approaches to obesity.
Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.
The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.
More from Global Vision
While Japan looks set to further improve policies to support ventures and ease market entry this year, these will contrast with ongoing reimbursement price controls.
As 2025 begins, the pharma industry is abuzz with discussions on pipeline strategies and China's growing role. With 30% of large pharma licensing deals now involving Chinese biotech, we take a whistlestop tour of the companies and regions driving this innovation.
As efforts to improve diversity in clinical trials gain momentum globally, regulators in the UK, the EU, Canada, Australia and Japan were asked about their efforts to support representative enrolment.